Emisphere to Present At New York Society of Security Analysts 12th Annual Biotech and Specialty Pharma Conference

• Press Release
• Source: Emisphere Technologies, Inc.
• On Monday December 1, 2008, 10:08 am EST

CEDAR KNOLLS, N.J., Dec. 1, 2008 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (NasdaqCM:EMIS - News), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(r) Technology, today announced that Michael V. Novinski, President and Chief Executive Officer, will present on December 2, 2008 at the New York Society of Security Analysts (NYSSA) 12th Annual Biotech and Specialty Pharma Conference, 1177 Avenue of the Americas, 2nd Floor, New York, New York. Mr. Novinski's presentation will take place at 11:30 AM EST.

Related Quotes

Symbol	Price	Change
EMIS.OB	0.93	+0.01

{"s" : "emis.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

A webcast of Mr. Novinski's presentation will be available on the NYSSA site approximately one week after the conference. For those interested in attending or learning more about the Conference, please visit the NYSSA website at: http://www.nyssa.org.

About Emisphere Technologies, Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(r) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(r) Technology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The website is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 13, 2008 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed on November 6, 2008.

          Emisphere Technologies, Inc.
          Bob Madison, Senior Director Corporate Communications
          973-532-8001
          bmadison@emisphere.com

          Adam Friedman Associates 
          Adam Friedman
          212-981-2529, extension 18
          adam@adam-friedman.com